1403-0002: MDM2 Inhibitor BI 907828 and Anti PD-1 Antibody Ezabenlimab in Select Solid Tumors

Condition: Solid Tumors

Sponsor: Boehringer Ingelheim

Full Title
Protocol 1403-0002: A phase Ia/Ib, open label, dose-escalation study of the combination of BI 907828 with BI 754091 (ezabenlimab) and BI 754111 and the combination of BI 907828 with BI 754091 (ezabenlimab) followed by expansion cohorts, in patients with advanced solid tumors

Study Treatment
MDM2 inhibitor BI 907828 + anti PD-1 antibody ezabenlimab

Eligibility/Info
Cohort 1: TP53 wild type soft tissue sarcoma (including liposarcoma excluding dedifferentiated liposarcoma, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, synovial sarcoma, leiomyosarcoma)
Cohort 2: MDM2 amplified, TP53 wild type non-small cell lung cancer, gastric adenocarcinoma, urothelial carcinoma, biliary tract carcinoma

Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.